论文部分内容阅读
目的探讨卵巢癌顺铂化疗耐药模型中14-3-3蛋白的差异表达,为深入研究卵巢癌顺铂耐药机制提供理论依据。方法分别提取卵巢癌顺铂耐药和敏感细胞的蛋白质,应用差异凝胶电泳(DIGE),通过DecyderTM分析软件获得差异表达蛋白质点,进行基质辅助激光解吸/电离飞行时间质谱(MALDI-TOF-MS)分析、鉴定。结果经过二维电泳技术分离,MALDI-TOF-MS成功鉴定出2个14-3-3蛋白亚型,即14-3-3σ和14-3-3ζ,在耐药细胞中表达分别上调31%和38%,t检验P值分别为0.0049和0.0032。结论差异蛋白14-3-3σ和14-3-3ζ的鉴定为探讨这类蛋白在卵巢癌顺铂耐药中的作用奠定了基础,并提供了候选治疗靶点。
Objective To investigate the differential expression of 14-3-3 protein in cisplatin-resistant ovarian cancer model and to provide a theoretical basis for further study on cisplatin-resistant mechanism of ovarian cancer. Methods Differential proteins (DIGE) were extracted from drug-resistant and sensitive cells of cisplatin-resistant ovarian cancer cells. Differentially expressed protein spots were detected by DecyderTM software and analyzed by matrix-assisted laser desorption / ionization time of flight mass spectrometry (MALDI-TOF- MS ) Analysis, identification. RESULTS: Two 14-3-3 protein subtypes (14-3-3σ and 14-3-3ζ) were successfully identified by MALDI-TOF-MS after two-dimensional electrophoresis. The expression in drug-resistant cells was up-regulated by 31% And 38% respectively. The t-test P values were 0.0049 and 0.0032, respectively. Conclusion The identification of different proteins 14-3-3σ and 14-3-3ζ lays a foundation for exploring the role of these proteins in cisplatin-resistant ovarian cancer and provides a potential therapeutic target.